292 related articles for article (PubMed ID: 8638354)
1. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
[TBL] [Abstract][Full Text] [Related]
2. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
3. Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
Liedberg F; Chebil G; Månsson W
Expert Rev Anticancer Ther; 2007 Mar; 7(3):383-90. PubMed ID: 17338657
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
5. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
6. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
7. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
9. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
[TBL] [Abstract][Full Text] [Related]
10. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
[TBL] [Abstract][Full Text] [Related]
12. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
[TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
14. [Transitional cell carcinoma in prostate after intravesical instillation of Bacillus Calmette-Guerin].
Ito Y; Nishiyama H; Higashi S; Kinoshita H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2004 May; 50(5):335-8. PubMed ID: 15237488
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Incidence, characteristics and preoperative detection.
Liedberg F; Anderson H; Bläckberg M; Chebil G; Davidsson T; Gudjonsson S; Jahnson S; Olsson H; Månsson W
Scand J Urol Nephrol; 2007; 41(4):290-6. PubMed ID: 17763219
[TBL] [Abstract][Full Text] [Related]
16. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
17. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR; Herr HW; Whitmore WF; Badalament RA; Kimmel M; Provet J; Oettgen HF; Melamed MR; Fair WR
J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
[TBL] [Abstract][Full Text] [Related]
19. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
20. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]